Concept information
Preferred term
ethics of placebo controls in multinational clinical trials
Definition
- During the past decade, there has been a heated controversy over the ethical justification of the use of placebo controls in clinical trials designed to develop, for use in countries with limited resources, to develop affordable alternatives for the expensive therapies used in the wealthy countries. This entry identifies the major themes in this controversy and then specifies the current understandings of this issue as they are expressed in the international codes of research ethics.1 Historical Considerations: The Problem as it Stood in 1996 The Declaration of Helsinki, the code of research ethics promulgated by the World Medical Association (WMA) in 1964 and since recognized widely as a leading code of ethics for biomedical research involving human subjects, contained in its 1996 iteration the following article on the use of placebos; this established the “best proven therapeutic method” as the standard requirement for all patients who serve as research subjects: II.3 In any medical study, every patient—including those of a control group, if any—should be assured of the best proven diagnostic and therapeutic method. [Source: Encyclopedia of Applied Developmental Science; Placebo Controls, Ethics in Multinational Clinical Trials]
Broader concept
Belongs to group
URI
https://concepts.sagepub.com/social-science/concept/ethics_of_placebo_controls_in_multinational_clinical_trials
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}